Reporting from ESMO Congress 2019, Christophe Tournigand comments on results from the subgroup, pooled and cohort analysis in the studies that show improvements in the response rate and overall survival with immune checkpoint inhibitors treatment in patients with Microsatellite Instability (MSI)-high tumours.
He emphasizes the importance of MSI testing in patients with gastrointestinal, endometrial and other cancer types.
Abstracts:
- 1174O: Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies
- LBA44: Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer (GC) Including Outcomes According to Microsatellite Instability-High (MSI-H) Status in KEYNOTE-062
- 1239P: High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
This video was supported with an educational grant from Roche. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.